This is a clinical trial study that will be performed to demonstrate the effect of raloxifen on serum level of parathyroid hormone on osteoporotic menopausal women with stage 3 to 5 of chronic kidney. Inclusion criteria: longer than 1 years of menopause; patients under treatment hemodialysis or CKD patients with GFR<=60; age older than 35 years.
Exclusion criteria were applied: previous HRT; venous occlusive disease; history of arteriovenous fistula thrombosis; cardiovascular disease, hepatic disease, or cancer; previous evidence of disease, other than chronic renal failure, that could affect bone metabolism; patients who had been recently treated with estrogen, progesterone, tibolone, corticosteroids, anticonvulsants, fluoride, bisphosphonates, or calcitonin; withdrawal of raloxifen for more than 4weeks.
After selecting the 60 cases, an informed consent will be obtained, the patients will be divided to two group that consist of 30 people and randomly matched by considering the level of parathyroid, age, count of hemodialysis and chronic kidney disease patients and during of menopause. The target parathyroid is described by KDOQI of 2007.
Designing the study is double-blinded and involved placebo and drug group. In all patients, we will perform a baseline bone mineral density analysis and simultaneously evaluated different biochemical parameters, serum levels of total calcium, phosphorus, alkaline phosphatase, blood urea nitrogen, creatinine and level of parathyroid hormone. Bone densitometry and all laboratory tests will be reassessed after 6-months of therapy. The patients will be given 60mg Raloxifen or placebo and dosage of calcium and vitamin-D are as the KDOQI guideline.